DA-125, a new antitumor agent, inhibits topoisomerase II as topoisomerase poison and DNA intercalator simultaneously.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002166:Camptothecin / Q000494:pharmacology; D002522:Chlorocebus aethiops; D004247:DNA / Q000737:chemistry / Q000187:drug effects*; D004261:DNA Replication / Q000187:drug effects / Q000502:physiology; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis / Q000494:pharmacology*; D019281:Dimerization; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005047:Etoposide / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000882:Haplorhini; D007364:Intercalating Agents / Q000494:pharmacology*; D008722:Methods; D014176:Protein Biosynthesis; D011506:Proteins / Q000737:chemistry; D013539:Simian virus 40 / Q000187:drug effects / Q000254:growth & development; D059005:Topoisomerase II Inhibitors; D014709:Vero Cells
D000970:Antineoplastic Agents; D007364:Intercalating Agents; D011506:Proteins; D059005:Topoisomerase II Inhibitors; C090816:7-O-(2,6-Dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride; D005047:Etoposide; D004317:Doxorubicin; D004247:DNA; D004250:DNA Topoisomerases, Type II; D002166:Camptothecin